$-0.98 EPS Expected for Versartis, Inc. (VSAR); Sucampo Pharmaceuticals (SCMP) Sentiment Is 1.65

February 15, 2018 - By Winifred Garcia

Analysts expect Versartis, Inc. (NASDAQ:VSAR) to report $-0.98 EPS on February, 20.They anticipate $0.34 EPS change or 53.13% from last quarter’s $-0.64 EPS. After having $-1.40 EPS previously, Versartis, Inc.’s analysts see -30.00% EPS growth. It closed at $1.725 lastly. It is down 103.18% since February 15, 2017 and is uptrending. It has outperformed by 86.48% the S&P500.

Sucampo Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing, identifying, acquiring, and marketing medicines that meet unmet medical needs, primarily in gastroenterology, ophthalmology, and oncology-related disorders in the United States, Japan, Switzerland, and internationally. The company has market cap of $847.54 million. The companyÂ’s marketed product includes AMITIZA , a ClC-2 chloride channel activator for the treatment of chronic idiopathic constipation (CIC) in adults, irritable bowel syndrome with constipation in adult women (IBS-C), and opioid-induced constipation (OIC)in patients with chronic non-cancer related pain; and RESCULA (unoprostone isopropyl), a big potassium channel activator for the treatment of glaucoma and ocular hypertension. It currently has negative earnings. The Company’s product candidates in clinical development stage comprise Lubiprostone that is in Phase III clinical trials for the treatment of pediatric functional constipation and (IBS-C); and completed Phase III clinical trials for the treatment of (CIC) in adults, IBS-C in adult women, and OIC in patients with chronic non-cancer pain, as well as CPP-1X/sulindac combination product, which has completed Phase III clinical trials for the treatment of familial adenomatous polyposis.

Since January 1, 0001, it had 0 insider purchases, and 3 insider sales for $24.83 million activity.

Ratings analysis reveals 67% of Sucampo Pharma’s analysts are positive. Out of 3 Wall Street analysts rating Sucampo Pharma, 2 give it “Buy”, 0 “Sell” rating, while 1 recommend “Hold”. The lowest target is $16.0 while the high is $19.0. The stock’s average target of $17.50 is -2.78% below today’s ($18) share price. SCMP was included in 3 notes of analysts from September 7, 2016. The stock of Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) has “Outperform” rating given on Wednesday, September 7 by Northland Capital. The stock of Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) earned “Buy” rating by Maxim Group on Tuesday, November 15. Mizuho maintained it with “Neutral” rating and $16.0 target in Monday, November 14 report.

Krensavage Asset Management Llc holds 10.42% of its portfolio in Sucampo Pharmaceuticals, Inc. for 2.83 million shares. Piermont Capital Management Inc. owns 178,570 shares or 0.7% of their US portfolio. Moreover, Malaga Cove Capital Llc has 0.58% invested in the company for 84,241 shares. The New York-based Clark Estates Inc Ny has invested 0.53% in the stock. Nea Management Company Llc, a Maryland-based fund reported 1.26 million shares.

It closed at $18 lastly. It is down 5.30% since February 15, 2017 and is downtrending. It has underperformed by 22.00% the S&P500.

Analysts await Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) to report earnings on March, 14. They expect $0.34 EPS, down 50.00% or $0.34 from last year’s $0.68 per share. SCMP’s profit will be $16.01 million for 13.24 P/E if the $0.34 EPS becomes a reality. After $0.27 actual EPS reported by Sucampo Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts 25.93% EPS growth.

Versartis, Inc. operates as an endocrine-focused biopharmaceutical firm in the United States. The company has market cap of $61.77 million. The firm is developing VRS-317, a long-acting recombinant human growth hormone, which is in Phase III clinical trials for the treatment of growth hormone deficiency. It currently has negative earnings. It develops drug candidates that it has licensed from Amunix Operating, Inc.

Investors sentiment decreased to 1.29 in 2017 Q3. Its down 0.10, from 1.39 in 2017Q2. It dived, as 25 investors sold Versartis, Inc. shares while 24 reduced holdings. 35 funds opened positions while 28 raised stakes. 16.86 million shares or 34.93% less from 25.90 million shares in 2017Q2 were reported. Moreover, Northern Trust Corp has 0% invested in Versartis, Inc. (NASDAQ:VSAR) for 403,573 shares. Bogle Investment Management L P De holds 72,320 shares or 0.01% of its portfolio. Hightower Advsrs Ltd Limited Liability Company holds 32,550 shares or 0% of its portfolio. Cornerstone Capital Mngmt Liability Corporation reported 24,214 shares or 0% of all its holdings. Royal Bankshares Of Canada has invested 0% in Versartis, Inc. (NASDAQ:VSAR). Millennium Mngmt Limited Company owns 765,836 shares for 0% of their portfolio. Golub Group Inc Limited Liability Corporation holds 0.01% or 40,000 shares in its portfolio. Switzerland-based Swiss Bank & Trust has invested 0% in Versartis, Inc. (NASDAQ:VSAR). Tci Wealth Advsrs Inc has invested 0% in Versartis, Inc. (NASDAQ:VSAR). New York State Common Retirement Fund invested in 71,615 shares or 0% of the stock. Rhumbline Advisers reported 0% in Versartis, Inc. (NASDAQ:VSAR). Schwab Charles Investment Mngmt, a California-based fund reported 99,818 shares. Manufacturers Life Insur The stated it has 16,606 shares. Great West Life Assurance Can holds 0% or 4,500 shares. Point72 Asset Limited Partnership holds 0% of its portfolio in Versartis, Inc. (NASDAQ:VSAR) for 100,000 shares.

Since September 21, 2017, it had 0 insider buys, and 5 selling transactions for $7.02 million activity. 667 shares were sold by Hislop Colin, worth $1,701. The insider Brumm Joshua T sold $3,381. Westberg Paul had sold 1,326 shares worth $3,381 on Thursday, October 19. The insider PERCEPTIVE ADVISORS LLC sold 2.13 million shares worth $7.01 million. The insider Ward Shane sold $1,979.

Among 12 analysts covering Versartis Inc (NASDAQ:VSAR), 6 have Buy rating, 1 Sell and 5 Hold. Therefore 50% are positive. Versartis Inc had 26 analyst reports since August 13, 2015 according to SRatingsIntel. The firm has “Underperform” rating by Credit Suisse given on Thursday, December 17. The stock of Versartis, Inc. (NASDAQ:VSAR) earned “Buy” rating by Canaccord Genuity on Monday, September 21. The stock of Versartis, Inc. (NASDAQ:VSAR) has “Buy” rating given on Friday, May 26 by Canaccord Genuity. The firm earned “Outperform” rating on Thursday, April 7 by Northland Capital. As per Friday, September 22, the company rating was downgraded by Citigroup. On Friday, September 22 the stock rating was downgraded by PiperJaffray to “Neutral”. Citigroup downgraded Versartis, Inc. (NASDAQ:VSAR) rating on Monday, September 25. Citigroup has “Hold” rating and $3.0 target. The stock has “Buy” rating by Canaccord Genuity on Friday, September 22. The rating was downgraded by SunTrust on Friday, September 22 to “Hold”. The firm has “Buy” rating given on Thursday, August 11 by Citigroup.

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Posts

>